Microfluidics Market Summary

The global microfluidics market size was estimated at USD 37.49 billion in 2024 and is anticipated to reach USD 73.85 billion by 2030, growing at a CAGR of 11.99% from 2025 to 2030. This growth is primarily driven by the increasing adoption of microfluidic devices across various fields of research and diagnostics. These devices offer advantages such as reduced sample volume requirements, faster analysis time, improved portability, and cost-effective testing solutions, making them highly suitable for both clinical and industrial applications.

For instance, in March 2025, a U.S.-based study introduced a microfluidics-based analytical technique improving detection accuracy and performance in chemical testing. It demonstrated strong potential to transform chemical analysis across multiple industries such as pharmaceuticals, environmental monitoring, and food safety. Microfluidic systems are already widely used in point-of-care testing platforms, enabling rapid analysis for glucose monitoring, infectious disease detection, and biomarker evaluation. They are also increasingly used to diagnose dry eye disease and assess vascular endothelial growth factor levels for ocular health. Such ongoing developments in healthcare diagnostics, combined with rising demand for miniaturized laboratory solutions, are expected to positively influence market growth in the coming years.

Key Market Trends & Insights

  • North America microfluidics market dominated the global market with a revenue share of 42.3% in 2024, supported by strong commercialization of advanced technologies and high adoption of automated diagnostic solutions.
  • Advanced healthcare infrastructure, robust research and development investments, and the presence of industry leaders drive the U.S. microfluidics market, strengthening its leadership in innovation and clinical deployment.
  • By material, the polydimethylsiloxane (PDMS) segment held the highest revenue share of 36.60% in 2024 due to its flexibility, biocompatibility, and ease of fabrication for microfluidic chips.
  • By technology, the lab-on-a-chip segment held the highest market share of 37.49% in 2024, benefiting from the increasing need for compact, faster, and highly sensitive diagnostic tools.
  • By product, the microfluidic components segment held the largest revenue share in 2024 and is anticipated to grow at the fastest CAGR over the forecast period owing to expanding production of consumables and integrated components required for continuous testing and research workflows.

Order a free sample PDF of the Microfluidics Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

  • 2024 Market Size: USD 37.49 Billion
  • 2030 Projected Market Size: USD 73.85 Billion
  • CAGR (2025-2030): 11.99%
  • North America: Largest market in 2024

Key Companies & Market Share Insights

The microfluidics market is characterized by several established players who dominate through strong product portfolios, strategic collaborations, and consistent R&D investments. Leading companies such as Danaher Corporation, Thermo Fisher Scientific, Agilent Technologies, and PerkinElmer have maintained significant market share due to their global presence and integrated solutions spanning diagnostics, drug discovery, and genomics.

Key Players

  • Illumina, Inc.
  • Hoffmann-La Roche Ltd
  • Revitty
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Danaher
  • Thermo Fisher Scientific, Inc.
  • Abbott
  • Standard Biotools
  • thinXXS Microtechnology GmbH

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

In conclusion, the global microfluidics market is poised for strong expansion as demand for rapid diagnostics, efficient analytical tools, and portable testing solutions continues to rise. Increasing use of microfluidic devices in fields such as clinical diagnostics, pharmaceutical development, and environmental testing supports sustained market momentum. North America remains the leading region due to advanced research facilities and early technology adoption, while investment in emerging healthcare markets also creates new growth avenues. Continuous focus on innovation in microfluidic materials, components, and lab-on-a-chip technology is expected to further enable cost-effective, precise, and scalable diagnostic solutions, ensuring long-term industry growth worldwide.